SCHEMBL21166472

SCHEMBL21166472

CCCCCCCC(C)(CCCC)CCN(C)C(=O)CCl

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.41
▸ TP53 P04637 2/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ PAX8 Q06710 2/20 0.41
▸ GPX4 P36969 1/20 0.41
▸ JAK2 O60674 1/20 0.39
▸ EPHX2 P34913 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ SMPD1 P17405 2/20 0.34
▸ DNM1 Q05193 2/20 0.34
▸ CES2 O00748 1/20 0.34
▸ FDPS P14324 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.33
▸ CNR1 P21554 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19176543 1.00 ALDH1A1 (0.41) ALDH1A1TP53NPC1RAB9APAX8
SCHEMBL19240716 0.98 ALDH1A1 (0.42) ALDH1A1TP53NPC1RAB9APAX8
SCHEMBL18857525 0.98 ALDH1A1 (0.42) ALDH1A1TP53NPC1RAB9APAX8
SCHEMBL20216159 0.95 ALDH1A1 (0.40) ALDH1A1TP53NPC1RAB9APAX8
SCHEMBL18743131 0.92 ALDH1A1 (0.35) ALDH1A1TP53NPC1RAB9APAX8
SCHEMBL24690677 0.89 ALDH1A1 (0.35) ALDH1A1TP53NPC1RAB9APAX8
SCHEMBL22420113 0.86 ALDH1A1 (0.40) ALDH1A1TP53NPC1RAB9APAX8
SCHEMBL19069153 0.84 ALDH1A1 (0.38) ALDH1A1TP53NPC1RAB9APAX8
SCHEMBL18737307 0.82 ALDH1A1 (0.36) ALDH1A1TP53NPC1RAB9APAX8
SCHEMBL9422721 0.79 NPC1 (0.51) ALDH1A1TP53NPC1RAB9APAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10618902-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases CELGENE CAR LLC (BM) 2020-04-14 — — US disclosed
US-20190218220-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2019-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218220-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC ALDH1A1 3719/4885TP53 46/4885NPC1 1614/4885
US-10618902-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases PDXK, DCK, DTYMK ALDH1A1 3786/4885TP53 934/4885NPC1 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback